Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces 2016 Financial Results and Provides Update on Company Progress

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 15, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with...
March 03, 2017 07:00 ET | Source: uniQure N.V.

uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award

-- Lexington, MA-based Gene Therapy Facility Recognized for Enabling Manufacturing Excellence -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V....
March 01, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces Presentations at Upcoming March Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
February 06, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces Presentations at Upcoming February Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced presentations at the following...
January 30, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that AMT-060, its proprietary,...
January 25, 2017 07:00 ET | Source: uniQure N.V.

uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 25, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Alexander Kuta,...
January 09, 2017 07:00 ET | Source: uniQure N.V.

uniQure Outlines Key Initiatives for 2017 and Vision for 2018

-- Preparations Underway for Late-Stage Development in Hemophilia B-- Three Clinical-Stage Programs by 2018 Including One Pivotal and Two Proof-of-Concept Studies-- Company Strengthened Following...
December 19, 2016 07:00 ET | Source: uniQure N.V.

uniQure Appoints Matthew Kapusta as Chief Executive Officer

uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its Board of Directors has unanimously approved the appointment of Matthew Kapusta as Chief Executive Officer...
December 03, 2016 15:51 ET | Source: uniQure N.V.

uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B

-- Second-dose Cohort Demonstrates Dose Response with All Patients Free of Prophylactic FIX Replacement Therapy and Only One Spontaneous Bleed Reported -- Low-Dose Cohort Shows Sustained...
December 02, 2016 07:04 ET | Source: uniQure N.V.

uniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School

Amsterdam, The Netherlands, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Lexington, MA and Amsterdam, the Netherlands, December 2, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today...